obesity and overweight

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultweight loss equal to or greater than 5 percent weight loss equal to or greater than 10 percent

All mechanism

not classified
Breum, 1995   Fluoxetineplacebo -
Connolly, 1995   Fluoxetineplacebo -
Darga, 1991   Fluoxetineplacebo -
Goldstein, 1994   Fluoxetineplacebo -
Gray, 1992   Fluoxetineplacebo -
Marcus, 1990   Fluoxetineplacebo -
Mendoza Espejo, 1995   Fluoxetineplacebo -
Michelson 50wk, 1999   Fluoxetineplacebo -
O’Kane, 1994   Fluoxetineplacebo -
APD356-004, 2009     lorcaserinplacebo -
Astrup     tesofensineplacebo -
Bupropion
Anderson, 2002     BupropionplaceboLow risk of bias -
Croft, 2002   Bupropionplacebo -
Jain, 2002     BupropionplaceboLow risk of bias -
liraglutide
Astrup (NN8022-1807 ), 2009    NCTliraglutideplaceboLow risk of bias -
lorcaserin
BLOSSOM (10mg bid), 2009      NCTlorcaserinplaceboLow risk of bias - 89%132%
BLOOM, 2010    NCTlorcaserinplaceboLow risk of bias - 134%194%
BLOOM-DM (10mg bid)    NCTlorcaserinplaceboLow risk of bias - 132%268%
orlistat
Bakris, 2002     OrlistatplaceboLow risk of bias -
Broom, 2002   OrlistatplaceboLow risk of bias -
Broom,, 2001   Orlistatplacebo -
Davidson, 1999     OrlistatplaceboLow risk of bias -
Deerochanawong,, 2001   Orlistatplacebo -
Derosa, 2003     OrlistatplaceboLow risk of bias -
Gotfredsen, 2001     Orlistatplacebo -
Halpern, 2003     OrlistatplaceboLow risk of bias -
Hanefeld, 2002     Orlistatplacebo -
Hauptman, 2000     OrlistatplaceboLow risk of bias -
Hill, 1999     OrlistatplaceboLow risk of bias -
Hollander, 1998     Orlistatplacebo -
Karhunen, 2000   Orlistatplacebo -
Kelley, 2002     OrlistatplaceboLow risk of bias -
Krempf, 2005     Orlistatplacebo -
Lindgarde, 2000     Orlistatplacebo -
Lucas, 2003     Orlistatplacebo -
Micic, 1999   OrlistatplaceboLow risk of bias -
Miles, 2002     OrlistatplaceboLow risk of bias -
Muls, 2001     OrlistatplaceboLow risk of bias -
Naumov, 2002   Orlistatplacebo -
Reaven, 2001     Orlistatplacebo -
Rissanen, 2001     OrlistatplaceboLow risk of bias -
Rosenfalck, 2002     Orlistatplacebo -
Rossner, 2000     OrlistatplaceboLow risk of bias -
Shi Yi, 2001   Orlistatplacebo -
Sjostrom, 1998     OrlistatplaceboLow risk of bias -
Vidgren, 1999   Orlistatplacebo -
phentermine and topiramate
CONQUER (high-dose) (OB 303)      NCTPHEN/TPM high doseplacebo -
OB 302 (high-dose)   PHEN/TPM high doseplacebo -
OB 301 (high-dose)   PHEN/TPM high doseplacebo -
OB 302 (low-dose)   PHEN/TPM low-doseplacebo -
OB 301 (mid-dose)   PHEN/TPM mid-doseplacebo -
CONQUER (mid-dose) (OB 303)      NCTPHEN/TPM mid-doseplacebo -
Sibutramine
McMahon, 2000     Sibutramineplacebo -
McMahon, 2002   Sibutramineplacebo -
Smith, 2001     Sibutramineplacebo -
SCOUT, 2010        NCTsibutramineplaceboLow risk of bias -
topiramate
Bray, 2003     Topiramateplacebo -
Caterson, 2003   Topiramateplacebo -
Pud’homme, 2003   Topiramateplacebo -
Rissanen, 2003   Topiramateplacebo -
Stenlof, 2003   Topiramateplacebo -
Tonstad, 2003   Topiramateplacebo -